CTI Xyotax PIONEER Study Closes In Favor Of Normal Estrogen Level Protocol
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cell Therapeutics will submit a new Xyotax (paclitaxel poliglumex) trial protocol to FDA by the end of the month after closing its Phase III PIONEER gender-specific lung cancer trial